AMBOSS, a Berlin-based platform dedicated to medical education and clinical decision-making, has successfully raised €240 million in a recent financing round. This significant investment facilitates the company’s expansion into new international markets and allows it to diversify its offerings, now including support for nurses and other healthcare professionals.
In a move to strengthen its legal presence, AMBOSS has transformed into a European stock corporation (SE), attracting fresh long-term investors. This round was spearheaded by KIRKBI, M&G Investments, and Lightrock, alongside existing stakeholders. Peter Bason from KIRKBI remarked, “We have followed AMBOSS’ impressive growth journey… Its unique platform is becoming a vital tool for… healthcare professionals.”
Founded in 2012 by Dr. Madjid Salimi and Benedikt Hochkirchen, AMBOSS provides both students and clinicians with a vast repository of medical knowledge. Its innovative platform features an interactive library and a comprehensive question bank, alongside evidence-based recommendations for clinical decisions, ultimately aiding in accurate patient care and efficient practice.
The platform, leveraging AI technologies, enhances educational experiences and provides reliable support for healthcare professionals. Co-founder Dr. Salimi emphasised that technology will not replace healthcare workers but will instead elevate those who adapt to it. AMBOSS is currently used by over 1 million professionals in 180 countries, and a substantial number of providers in Germany and the US have integrated it into their practice and exam preparations.
Co-founder Benedikt Hochkirchen expressed the company’s commitment to partnering with investors who share a long-term vision. He noted, “Many of our new investors manage evergreen funds and plan… until a possible IPO and beyond.” The funds from this financing round are earmarked for further technological advancements and strategic acquisitions, including the purchase of Novaheal and NEJM Knowledge+ to broaden AMBOSS’s reach and capabilities.
AMBOSS, a Berlin-based medical education platform, has raised €240 million to expand internationally and diversify its offerings for healthcare professionals, including nurses. The investment led by KIRKBI, M&G Investments, and Lightrock highlights the platform’s growth and importance in medical education. Co-founders Dr. Salimi and Hochkirchen aim to enhance technology and support through this new funding.
In conclusion, AMBOSS has successfully secured €240 million in funding to propel its expansion and drive innovation in medical education. The support from new long-term investors signals confidence in its vision and the potential for further growth, especially in catering to nursing and healthcare professionals. With a focus on leveraging technology to enhance both learning and clinical decision-making, AMBOSS is set to continue its impressive trajectory in the global healthcare landscape.
Original Source: siliconcanals.com
